Last Updated : October 9, 2019
Details
Generic Name:
tofacitinib
Project Status:
Cancelled
Manufacturer:
Pfizer Canada Inc.
Call for patient/clinician input open:
Brand Name:
Xeljanz
Project Line:
Reimbursement Review
Project Number:
SR0575-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with active psoriatic arthritis (PsA) when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
Arthritis, Psoriatic
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : October 9, 2019